Chemically Induced Degradation of WEE1 Kinase for Difficult to Treat Diseases.
作者信息
Kargbo Robert B
机构信息
Usona Institute, 277 Granada Drive, San Luis Obispo, California 93401-7337, United States.
出版信息
ACS Med Chem Lett. 2020 Jul 9;11(8):1494-1495. doi: 10.1021/acsmedchemlett.0c00345. eCollection 2020 Aug 13.
Abstract
摘要
相似文献
1
Chemically Induced Degradation of WEE1 Kinase for Difficult to Treat Diseases.化学诱导的WEE1激酶降解用于治疗难治性疾病。
ACS Med Chem Lett. 2020 Jul 9;11(8):1494-1495. doi: 10.1021/acsmedchemlett.0c00345. eCollection 2020 Aug 13.
2
Activation domain-dependent degradation of somatic Wee1 kinase.依赖激活结构域的体细胞 Wee1 激酶降解。
J Biol Chem. 2010 Feb 26;285(9):6761-9. doi: 10.1074/jbc.M109.093237. Epub 2009 Dec 28.
3
GSK3 inhibitors stabilize Wee1 and reduce cerebellar granule cell progenitor proliferation.糖原合成酶激酶3抑制剂可稳定Wee1并减少小脑颗粒细胞祖细胞的增殖。
Cell Cycle. 2015;14(3):417-24. doi: 10.4161/15384101.2014.974439.
4
Casein kinase 1δ-dependent Wee1 protein degradation.酪蛋白激酶1δ依赖的Wee1蛋白降解
J Biol Chem. 2014 Jul 4;289(27):18893-903. doi: 10.1074/jbc.M114.547661. Epub 2014 May 9.
5
Targeting the WEE1 kinase strengthens the antitumor activity of imatinib via promoting KIT autophagic degradation in gastrointestinal stromal tumors.靶向 WEE1 激酶通过促进胃肠道间质肿瘤中 KIT 的自噬降解增强伊马替尼的抗肿瘤活性。
Gastric Cancer. 2020 Jan;23(1):39-51. doi: 10.1007/s10120-019-00977-1. Epub 2019 Jun 13.
7
An ultra-high throughput cell-based screen for wee1 degradation inhibitors.一种用于wee1降解抑制剂的超高通量细胞筛选。
J Biomol Screen. 2010 Sep;15(8):907-17. doi: 10.1177/1087057110375848. Epub 2010 Jul 26.
8
Mapping of the interaction sites between Wee1 kinase and the regulatory beta-subunit of protein kinase CK2.Wee1 激酶与蛋白激酶 CK2 的调节β亚基相互作用位点的作图。
Int J Oncol. 2010 May;36(5):1175-82. doi: 10.3892/ijo_00000600.
9
WEE1 kinase protects the stability of stalled DNA replication forks by limiting CDK2 activity.WEE1 激酶通过限制 CDK2 的活性来保护停滞的 DNA 复制叉的稳定性。
Cell Rep. 2022 Jan 18;38(3):110261. doi: 10.1016/j.celrep.2021.110261.
10
Design, synthesis, and biological evaluation of Wee1 kinase degraders.设计、合成及 Wee1 激酶降解剂的生物学评估。
Eur J Med Chem. 2022 Dec 5;243:114786. doi: 10.1016/j.ejmech.2022.114786. Epub 2022 Sep 22.
本文引用的文献
1
WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.WEE1 激酶限制 CDK 活性以保护 DNA 复制和有丝分裂进入。
Mutat Res. 2020 Jan-Apr;819-820:111694. doi: 10.1016/j.mrfmmm.2020.111694. Epub 2020 Feb 25.
2
Expanding the Degradable Proteome: Designing PROTACs by the Book.扩展可降解蛋白质组：按图索骥设计 PROTACs。
Cell Chem Biol. 2020 Jan 16;27(1):14-16. doi: 10.1016/j.chembiol.2019.12.009.
3
Development and Characterization of a Wee1 Kinase Degrader.开发并鉴定一种 Wee1 激酶降解剂。
Cell Chem Biol. 2020 Jan 16;27(1):57-65.e9. doi: 10.1016/j.chembiol.2019.10.013. Epub 2019 Nov 14.
4
WEE1 kinase inhibitor shows promise.WEE1激酶抑制剂显示出前景。
Nat Rev Clin Oncol. 2019 Oct;16(10):593. doi: 10.1038/s41571-019-0270-9.
5
Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy.AZD1775，一种 Wee1 激酶抑制剂，用于癌症治疗的策略性开发。
Expert Opin Investig Drugs. 2018 Sep;27(9):741-751. doi: 10.1080/13543784.2018.1511700. Epub 2018 Aug 21.
6
Regulation of G2/M Transition by Inhibition of WEE1 and PKMYT1 Kinases.抑制 WEE1 和 PKMYT1 激酶对 G2/M 期转换的调控。
Molecules. 2017 Nov 23;22(12):2045. doi: 10.3390/molecules22122045.
Zotero 插件